Recent medical device IPOs have fallen in value an average of 14%; but even at their current low valuations, returns to private investors remain healthy. For this reason, it is likely that new IPOs will be priced far closer to the valuations of the last private rounds than they were in the IPOs of 1996-97. This Start-Up analysis also reveals that, contrary to conventional industry wisdom, companies who went public with earlier stage products have generated higher returns to both private and public investors.
by Stephen Levin and Roger Longman
What a difference a year makes—in 1996, two-thirds of the attendees at the annual fall Phoenix conference for medical device...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.
The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.
NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.
Ahead of the ADA conference, Abbott announced Tandem as the fourth partner to integrate Abbott’s dual glucose-ketone sensor with automated insulin delivery. Expanded Medicare CGM coverage, FDA label expansions and new ADA guidelines position Abbott to grow its CGM footprint in a competitive market.
NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.
Ahead of the ADA conference, Abbott announced Tandem as the fourth partner to integrate Abbott’s dual glucose-ketone sensor with automated insulin delivery. Expanded Medicare CGM coverage, FDA label expansions and new ADA guidelines position Abbott to grow its CGM footprint in a competitive market.
"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.
